Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail tested in fight against advanced liver cancer

NCT ID NCT05337137

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding a third drug (relatlimab) to a standard two-drug treatment (nivolumab and bevacizumab) is safe and more effective for people with untreated advanced liver cancer. It involved 83 participants who were randomly assigned to receive either the three-drug or two-drug combination. The main goals were to check for serious side effects and see if the three-drug combo led to better tumor shrinkage.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0001

    Nice, 06202, France

  • Local Institution - 0002

    Reims, 51092, France

  • Local Institution - 0003

    Padua, 35128, Italy

  • Local Institution - 0004

    Hong Kong, 0, Hong Kong

  • Local Institution - 0007

    Santander, Cantabria, 39008, Spain

  • Local Institution - 0008

    Rennes, 35042, France

  • Local Institution - 0009

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0010

    Roma, 00168, Italy

  • Local Institution - 0012

    Grenoble, 38043, France

  • Local Institution - 0013

    Melbourne, Victoria, 3065, Australia

  • Local Institution - 0016

    Warsaw, Masovian Voivodeship, 02-034, Poland

  • Local Institution - 0017

    Nedlands, Western Australia, 6009, Australia

  • Local Institution - 0018

    Singapore, 308433, Singapore

  • Local Institution - 0019

    San Juan, 00927, Puerto Rico

  • Local Institution - 0021

    Avignon, Cedex 9, 84918, France

  • Local Institution - 0022

    Adelaide, South Australia, 5000, Australia

  • Local Institution - 0023

    Gdansk, 80-219, Poland

  • Local Institution - 0024

    Taichung, 40705, Taiwan

  • Local Institution - 0025

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0026

    Heidelberg, Victoria, 3084, Australia

  • Local Institution - 0027

    Singapore, 217562, Singapore

  • Local Institution - 0028

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Local Institution - 0029

    Singapore, 168583, Singapore

  • Local Institution - 0030

    Washington D.C., District of Columbia, 20007, United States

  • Local Institution - 0031

    Shatin, 999077, Hong Kong

  • Local Institution - 0032

    Santiago de Compostela, A Coruña, 15706, Spain

  • Local Institution - 0033

    Milwaukee, Wisconsin, 53226, United States

  • Local Institution - 0034

    San Francisco, California, 94115, United States

  • Local Institution - 0035

    Frankfurt, 60590, Germany

  • Local Institution - 0036

    Milan, 20122, Italy

  • Local Institution - 0037

    Seongnam-si, Gyeonggido, 13496, South Korea

  • Local Institution - 0038

    Pamplona, 31008, Spain

  • Local Institution - 0039

    Los Angeles, California, 90095, United States

  • Local Institution - 0040

    Zaragoza, 50009, Spain

  • Local Institution - 0041

    Sayama, Osaka, 5898511, Japan

  • Local Institution - 0042

    Los Angeles, California, 90033, United States

  • Local Institution - 0043

    District Taichung City, Tai Zhong Shi, 404, Taiwan

  • Local Institution - 0044

    Singapore, 329563, Singapore

  • Local Institution - 0045

    Camperdown, New South Wales, 2050, Australia

  • Local Institution - 0046

    Taipei, 10048, Taiwan

  • Local Institution - 0047

    Kashiwa-shi, Chiba, 2778577, Japan

  • Local Institution - 0048

    Matsuyama, Ehime, 7900024, Japan

  • Local Institution - 0049

    Taipei, 11217, Taiwan

  • Local Institution - 0050

    Yokohama, Kanagawa, 2320024, Japan

  • Local Institution - 0051

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Local Institution - 0052

    Rio Piedras, PR, 935, Puerto Rico

  • Local Institution - 0053

    Madrid, 28046, Spain

  • Local Institution - 0054

    Suresnes, 92151, France

  • Local Institution - 0055

    Munich, 81377, Germany

  • Local Institution - 0056

    Seoul, 138-736, South Korea

  • Local Institution - 0057

    Mainz, 55131, Germany

  • Local Institution - 0058

    Kanazawa, Ishikawa-ken, 9208641, Japan

  • Local Institution - 0059

    Baltimore, Maryland, 21231, United States

  • Local Institution - 0060

    Boston, Massachusetts, 02114, United States

  • Local Institution - 0061

    New York, New York, 10065, United States

  • Local Institution - 0062

    The Bronx, New York, 10461, United States

  • Local Institution - 0063

    Chuo-ku, Tokyo, 104-0045, Japan

  • Local Institution - 0064

    Guangzhou, Guangdong, 510515, China

  • Local Institution - 0065

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0066

    Xi'an, Shan3xi, 710700, China

  • Local Institution - 0067

    Madrid, Sede Madrid, 28027, Spain

Conditions

Explore the condition pages connected to this study.

CARCINOMA, HEPATOCELLULAR